Heldner, Alexander
Heath, Matthew D.
Schnautz, Benjamin
Kotz, Sebastian
Chaker, Adam
Kramer, Matthias F.
Jakwerth, Constanze A.
Zissler, Ulrich M.
Schmidt-Weber, Carsten B.
Blank, Simon http://orcid.org/0000-0002-5649-1078
Funding for this research was provided by:
Helmholtz-Gemeinschaft (ZT-0027)
Bencard Allergie GmbH
Klinikum rechts der Isar der Technischen Universität München
Article History
Accepted: 18 January 2022
First Online: 3 February 2022
Declarations
:
: The study was approved by the local ethics committee of the Faculty of Medicine of the Technical University of Munich (299/15 s), and all the patients and volunteers gave written informed consent prior to study participation. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: Not applicable.
: Simon Blank reports grants and personal fees from Bencard Allergie GmbH, grants and personal fees from Thermo Fisher Scientific, and grants from Allergy Therapeutics, outside the submitted work. Adam Chaker reports grants and other from Allergopharma, from ALK Abello, Bencard/Allergy Therapeutics, ASIT Biotech, Lofarma, GSK, Novartis, LETI, Roche, Zeller, Sanofi Genzyme/Regeneron, European Institute of Technology, AstraZeneca, and Immunotek, all outside the submitted work. Matthew D. Heath and Matthias F. Kramer are employees of Allergy Therapeutics plc/Bencard Allergie GmbH, which supported this work. Further, Allergy Therapeutics plc/Bencard Allergie GmbH is a manufacturer of allergen immunotherapy and synbiotic products. Carsten B. Schmidt-Weber reports personal fees from Bencard and personal fees from Allergopharma, outside the submitted work. The other authors declare no competing interests.